Exclusive: U.S. insurer caught on to odd billing at Valeant-linked pharmacy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant Pharma (VRX) At Lows Into the Close
November 4, 2015 3:43 PM ESTValeant Pharma (NYSE: VRX) is trading near the lows into the close. Shares are down 6% to $92. Today's senate hearing on drug pricing, the 'missing piece' hit piece and reports from Reuters that OptumRx caught on to odd billing at Valeant-linked pharmacy more than a year ago, are all weighting.
... More